Tags

Type your tag names separated by a space and hit enter

Chronome of urinary 6-sulfoxy-melatonin excretion, circulating CA125, cancer progression and therapeutic response.
In Vivo. 1995 Jul-Aug; 9(4):375-8.V

Abstract

The longitudinal follow-up of a patient with an advanced adenocarcinoma of the ovary sheds new light on the involvement of the pineal in carcinogenesis. The changes in the circadian MESOR of 6-sulfoxy-melatonin following a course of chemotherapy may differ in relation to the success or failure of treatment, yet the MESOR does not correlate with tumor burden assessed by circulating CA125. By contrast, the ratio of circaseptan-to-circadian amplitudes involving two chronome components correlates with the cancer marker. To that extent, the study reveals a critical about 7-day (circaseptan) aspect of the pineal involvement in cancer progression. This information could be exploited in designing schedules of melatonin administration to cancer patients.

Authors+Show Affiliations

Chronobiology Laboratories, University of Minnesota, Minneapolis, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8555437

Citation

Cornélissen, G, et al. "Chronome of Urinary 6-sulfoxy-melatonin Excretion, Circulating CA125, Cancer Progression and Therapeutic Response." In Vivo (Athens, Greece), vol. 9, no. 4, 1995, pp. 375-8.
Cornélissen G, Berg H, Haus E, et al. Chronome of urinary 6-sulfoxy-melatonin excretion, circulating CA125, cancer progression and therapeutic response. In Vivo. 1995;9(4):375-8.
Cornélissen, G., Berg, H., Haus, E., & Halberg, F. (1995). Chronome of urinary 6-sulfoxy-melatonin excretion, circulating CA125, cancer progression and therapeutic response. In Vivo (Athens, Greece), 9(4), 375-8.
Cornélissen G, et al. Chronome of Urinary 6-sulfoxy-melatonin Excretion, Circulating CA125, Cancer Progression and Therapeutic Response. In Vivo. 1995 Jul-Aug;9(4):375-8. PubMed PMID: 8555437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chronome of urinary 6-sulfoxy-melatonin excretion, circulating CA125, cancer progression and therapeutic response. AU - Cornélissen,G, AU - Berg,H, AU - Haus,E, AU - Halberg,F, PY - 1995/7/1/pubmed PY - 1995/7/1/medline PY - 1995/7/1/entrez SP - 375 EP - 8 JF - In vivo (Athens, Greece) JO - In Vivo VL - 9 IS - 4 N2 - The longitudinal follow-up of a patient with an advanced adenocarcinoma of the ovary sheds new light on the involvement of the pineal in carcinogenesis. The changes in the circadian MESOR of 6-sulfoxy-melatonin following a course of chemotherapy may differ in relation to the success or failure of treatment, yet the MESOR does not correlate with tumor burden assessed by circulating CA125. By contrast, the ratio of circaseptan-to-circadian amplitudes involving two chronome components correlates with the cancer marker. To that extent, the study reveals a critical about 7-day (circaseptan) aspect of the pineal involvement in cancer progression. This information could be exploited in designing schedules of melatonin administration to cancer patients. SN - 0258-851X UR - https://www.unboundmedicine.com/medline/citation/8555437/Chronome_of_urinary_6_sulfoxy_melatonin_excretion_circulating_CA125_cancer_progression_and_therapeutic_response_ L2 - https://medlineplus.gov/ovariancancer.html DB - PRIME DP - Unbound Medicine ER -